ArticleJournal of veterinary internal medicine2026
Serum pancreatitis-associated protein 1 concentrations in dogs with acute signs of gastrointestinal disease and normal or abnormal DGGR lipase activity.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatitis-associated protein (PAP-1) is synthesized during acute pancreatitis (AP) and chronic enteropathy in people. Serum PAP-1 concentration (PAP-1) has not been measured prospectively in dogs.
objectivesEvaluate whether PAP-1 differentiates suspected AP (sAP) diagnosed by abnormal DGGR-lipase activity from non-pancreatic acute gastrointestinal disease (aGId) diagnosed by normal DGGR-lipase activity. ANIMALS: Twenty-six dogs with sAP, 48 dogs with aGId based on signs of acute gastrointestinal disease, lipase activity > 450 U/L (reference interval [RI],17-156 U/L) and maximally 20 U/L > RI, respectively. Forty healthy control dogs.
methodsProspective daily assessment included a simplified modified canine activity index (MCAI). PAP-1, lipase activity, C-reactive protein concentration (CRP) were measured daily. PAP-1 assay validation comprised precision, interferences, linearity, and RI establishment.
resultsLower/upper PAP-1 quantification limits were 0.2 and 6.0 μg/mL, linearity was excellent (R2 0.999) at high, acceptable (R2 0.966) at low PAP-1 concentrations. Intra-, inter-run precision was ≤5%, ≤22%, PAP-1 remained stable for 15 days (room temperature), no interferences were found. Duration of hospitalization and clinical disease severity did not differ between groups. At admission, PAP-1 above RI in 50% and 48 % of sAP and aGId dogs, respectively (sAP median, range 1.88 μg/mL, 0.2-6.0 vs. aGId 1.57 μg/mL, 0.2-6.0; RI, <1.9 μg/mL). PAP-1 did not differ significantly between groups irrespective of observation time points. PAP-1 correlated significantly with CRP in sAP (rs = 0.623) and aGId (rs = 0.483). PAP-1 correlated significantly with lipase activity (rs = 0.474) in sAP, with MCAI (rs = 0.342) in aGId. CONCLUSION AND CLINICAL IMPORTANCE: Serum PAP-1 reflects inflammation rather than underlying disease processes, and does not differentiate sAP from aGId.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.